Teena Thacker
Following a recent study by the Journal of American Medical Association (JAMA), stating that anti-diabetic drug Rosiglitazone may be associated with an increased risk of life-threatening diseases, the Drug Controller General of India (DCGI) on Friday put on hold the clinical trails of the drug going on at 10 centres in the country.
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/trials-anti-diabetic-drug-put-hold
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/indian-express-new-delhi
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health-care
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/diabetes
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/india